Testing D-galactose for PGM1-CDG in adults
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 2 study tests whether taking D-galactose is safe and helps symptoms or health markers in people with PGM1-CDG, a rare genetic condition. Participants must already be on a stable D-galactose dose to compare outcomes during the trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old.
- Have PGM1-CDG proven by genetic and lab testing.
- Be on a stable (unchanged) dose of D-galactose right now.
- If you can become pregnant (or have a pregnancy-capable partner), agree to very reliable birth control during the study and the long follow-up.
- Be able to understand the study and sign written consent (and assent if needed).
- Have no major excluded conditions or safety issues, like certain liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding D-galactose can help people with a confirmed SLC35A2 genetic condition. It aims to improve symptoms such as seizures and ongoing stomach problems like vomiting or diarrhea.
This study is for people who already completed a previous trial of GLM101 for PMM2-CDG. It offers continued access to the treatment while doctors monitor safety and effects.
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
This trial tests whether giving a gene therapy before birth can help babies with GM1 gangliosidosis, a rare genetic disorder that damages the brain and body. It uses a harmless virus to deliver a working copy of the missing enzyme, aiming to slow or prevent disease progression.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
This trial tests if the oral drug migalastat is safe and works for children aged 2 to under 12 with a specific type of Fabry disease. It may be an option if your child has not been on enzyme therapy recently and has a compatible gene variant.
Hear when a new PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.